Jurnalul de Chirurgie
 Jurnalul de chirurgie
Aparitie trimestriala in a doua luna a trimestrului
Published quarterly in the second month of the quarter
ISSN: 1584 - 9341 Vol.10 Nr.3 - Iulie-Septembrie 2014 | sâmbătă, 23 martie 2019
ISSN: 1584 - 9341 Vol.10 No.3 - July-September 2014
English
British Flag| Romana Romanian Flag
 
Creditare EMC
Colegiul Medicilor
Va invitam sa va inregistrati/abonati la Jurnalul de chirurgie pentru a beneficia de creditare EMC
User

Parola

Tine minte
Ti-ai uitat parola?
Syndicate

Advertisement

Elmed

Estima

Liamed

Listare E-mail

QUALITY OF LIFE OF WOMEN RECIEVING ADJUVANT HORMONAL TREATMENT FOR BREAST CANCER – A RANDOMIZED TRIAL COMPARING TAMOXIFEN WITH AROMATASE INHIBITORS
C. Volovat (1*), Simona Ruxandra Volovat (1), Carmen Vulpoi (2),
Cristina Gena Dascălu (2), Elena Mihaela Cărăuşu (2)
(1) Center of Medical Oncology, Iasi;
(2) University of Medicine and Pharmacy “Gr.T.Popa”, Iasi
Jurnalul de chirurgie 2011; 7 (2): 193-202
Full text:
Format PDF (Română/Romanian)

Abstract:

Purpose: The assessment and comparison of the quality of life in women with early stages breast cancer receiving Tamoxifen versus aromatase inhibitors (AINs). Methods: There were selected 223 patients treated at Center of Medical Oncology Iasi, with early stages breast cancer. The patients were divided in two groups: 115 patients receiving Tamoxifen and 107 patients receiving aromatase inhibitors. From the patients receiving AINs, 33 of patients have received Exemestane, 60 patients Letrozole and 14 patients Anastrazole. The patients have completed an EORTC C30 and EORTC BR23 questionnaire at the beginning of the treatment (after one month) and after 2 years of treatment. There was calculated the difference related with global status, functional scales, emotional scales, cognitive scales and symptom scales. Results: Statistic results show a better quality of life for Anastrazole vs. Letrozole and for AINs vs. Tamoxifen group, mainly on physical scales both after 2 months and after 2 years of treatment. In the same time, the physical scales were with better results after 1 month of treatment vs. 2 years of treatment. Conclusions: Following the hormonal treatment period, there is a mild worsening of quality of life for Tamoxifen and AINs too. In the same time, the quality of life is better in the group with AINs treatment comparative with the Tamoxifen treatment.

KEY WORDS: QUALITY OF LIFE, AROMATASE INHIBITORS, TAMOXIFEN

Correspondence to: Constantin Volovat, MD,PhD, Center of Medical Oncology Iasi, Str. Vasile Conta 2, et.3, cam.248, Iasi, 700106, Romania, e-mail:



: Creative Commons License
Jurnalul de chirurgie [Journal of Surgery] by Editorial Board, Department of Surgery University of Medicine and Pharmacy Iasi, E. Tarcoveanu, R. Moldovanu is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Based on a work at www.jurnaluldechirurgie.ro.